ModernMedicine Resource Center More Topics

Hepatology Resource Center

DAAs dramatically increase HCV cure rates among veteransThe introduction of direct-acting antiviral agents has transformed hepatitis C care among veterans.
Multiple DAAs provide quality care for HCV patientsMultiple oral direct-acting antiviral agents show great promise in treating the vast majority of hepatitis C patients.
Real-world DAA therapy shows gains in community settingPhysicians have a “good, effective, safe therapy available” for hepatitis C virus genotype 6 patients, says researcher.
Study: DAA all-oral combination successful in treating hepatitis CEarly data shows promise in “real-world” effectiveness.
DAAs do not increase risk of hepatic decompensation in HCV patientsResearchers say theirs is first national study with a large population to examine possible link.
DAA therapy effective in advanced liver disease in real-world studyAll-oral sofosbuvir-based therapy proves a significant advance for hepatitis C virus patients.
Researchers unveil optimal timing of HCV therapy in transplantationA new study by Yale researchers reveals the optimal timing for hepatitis C virus therapy in patients eligible for a liver transplant.
Oral DAA combination found effective in HCV patientsDirect-acting antiviral combination “represents an excellent treatment option” in some cases, says study’s senior author.
DAAs aid treatment of hepatitis C patients with cancerDirect-acting antiviral agents can be safely administered with chemotherapy in patients with hepatitis C virus, according to new research.
DAA treatment restricted for Canadian hepatitis C patientsPatients with hepatitis C virus (HCV) in Canada are limited in their access to direct-acting antiviral agents, according to researchers.